Topotecan Plus Carboplatin In Comparison To Standard Therapy (Paclitaxel Plus Carboplatin Or Gemcitabine Plus Carboplatin) In The Therapy Of Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer, Peritoneal Carcinoma or fallopian tube cancer

Trial Profile

Topotecan Plus Carboplatin In Comparison To Standard Therapy (Paclitaxel Plus Carboplatin Or Gemcitabine Plus Carboplatin) In The Therapy Of Patients With Platinum Sensitive Recurrent Epithelial Ovarian Cancer, Peritoneal Carcinoma or fallopian tube cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Carboplatin (Primary) ; Topotecan (Primary) ; Doxorubicin; Gemcitabine; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HECTOR
  • Most Recent Events

    • 26 Oct 2016 Results assessing tolerabilty of combination of Topotecan and Carboplatin published in the Annals of Oncology (2016).
    • 14 Nov 2013 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 26 Jul 2012 Planned end date changed from 1 Sep 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top